MWVC
MYGN icon

Morgens Waterfall Vintiadis & Co’s Myriad Genetics MYGN Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-150,000
Closed -$5.13M – 45
2014
Q1 		$5.13M Buy
+150,000
New +$4.65M 3.11% 7

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Tiger Global Management
Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's MYGN Position: Q2 2014 in Review

Morgens Waterfall Vintiadis & Co sold out of Myriad Genetics (MYGN) in Q2 2014, closing a stake of 150,000 shares — an estimated $5.13M sold.

Morgens Waterfall Vintiadis & Co first reported a position in MYGN in Q1 2014 and held it in 1 quarter. The position peaked at $5.13M in Q1 2014. 283 funds tracked by Wall St. Rank hold MYGN as of Q2 2014.

  • Morgens Waterfall Vintiadis & Co reported no remaining Myriad Genetics position as of Q2 2014 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 150,000 Myriad Genetics shares in Q2 2014, an estimated $5.13M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Myriad Genetics in Q1 2014 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's Myriad Genetics position peaked at $5.13M in Q1 2014.
  • 283 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2014.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q2 2014, filed 30 Jul 2014.